N-acetylcysteine improves antitumoural response of Interferon alpha by NF-kB downregulation in liver cancer cells

Comparative Hepatology

Volumn 11, Issue 1, 2012, Pages

  Kretzmann, Nelson Alexandre ^a,b   Chiela, Eduardo ^c,d   Matte, Ursula ^b   Marroni, Norma ^b   Marroni, Claudio Augusto ^a  

^a UNIVERSIDADE FEDERAL DE CIÊNCIAS DA SAÚDE DE PORTO ALEGRE   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

^c FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^d Universidade Federal do Rio Grande do Sul ^*

Author keywords

Interferon alpha; Liver cancer cells; N acetylcysteine; NF kB

Indexed keywords

ACETYLCYSTEINE; ALPHA2A INTERFERON; ANNEXIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMA CELL; CELL ASSAY; CELL STRUCTURE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG POTENTIATION; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; LIVER CELL CARCINOMA; PROTEIN EXPRESSION; RNA INTERFERENCE; TRANSCRIPTION REGULATION;

EID: 84870376274     PISSN: None     EISSN: 14765926     Source Type: Journal    
DOI: 10.1186/1476-5926-11-4     Document Type: Article

References (54)

1. Pache I, Bize P, Halkic N, Montemurro M, Giostra E, Majno P, Moradpour D. [Management of hepatocellular carcinoma]. Rev Med Suisse 2010, 6:198-202.
2. Cervello M, Montalto G. Cyclooxygenases in hepatocellular carcinoma. World J Gastroenterol 2006, 12:5113-5121.
3. Jain S, Singhal S, Lee P, Xu R. Molecular genetics of hepatocellular neoplasia. Am J Transl Res 2010, 2:105-118. 2826827, 20182587.
4. Hoshida Y, Toffanin S, Lachenmayer A, Villanueva A, Minguez B, Llovet J. Molecular Classification and Novel Targets in Hepatocellular Carcinoma: Recent Advancements. Semin Liver Dis 2010, 30:35-51. 10.1055/s-0030-1247131, 20175032.
5. El-Bassiouni A, Nosseir M, Zoheiry M, El-Ahwany E, Ghali A, El-Bassiouni N. Immunohistochemical expression of CD95 (Fas), c-myc and epidermal growth factor receptor in hepatitis C virus infection, cirrhotic liver disease and hepatocellular carcinoma. APMIS 2006, 114:420-427. 10.1111/j.1600-0463.2006.apm_323.x, 16856963.
6. Nguyen H, Sankaran S, Dandekar S. Hepatitis C virus core protein induces expression of genes regulating immune evasion and anti-apoptosis in hepatocytes. Virology 2006, 354:58-68. 10.1016/j.virol.2006.04.028, 16876223.
7. Goldstein D, Laszlo J. The role of interferon in cancer therapy: a current perspective. CA Cancer J Clin 1988, 38:258-277. 10.3322/canjclin.38.5.258, 2458171.
8. Zhuang P, Zhang J, Zhang W, Zhu X, Liang Y, Xu H, Xiong Y, Kong L, Wang L, Wu W, Tang Z, Qin L, Sun H. Long-term interferon-alpha treatment suppresses tumor growth but promotes metastasis capacity in hepatocellular carcinoma. J Cancer Res Clin Oncol 2010, 136:1891-1900. 10.1007/s00432-010-0848-1, 20213095.
9. Guo L, Guo Y, Xiao S. Expression of tyrosine kinase Etk/Bmx and its relationship with AP-1- and NF-kappaB-associated proteins in hepatocellular carcinoma. Oncology 2007, 72:410-416. 10.1159/000113491, 18196928.
10. Zingarelli B, Sheehan M, Wong HR. Nuclear factor-kappaB as a therapeutic target in critical care medicine. Crit Care Med 2003, 31:S105-S111. 10.1097/00003246-200301001-00015, 12544984.
11. Dutta J, Fan Y, Gupta N, Fan G, Gélinas C. Current insights into the regulation of programmed cell death by NF-kappaB. Oncogene 2006, 25:6800-6816. 10.1038/sj.onc.1209938, 17072329.
12. Tas S, Vervoordeldonk M, Tak P. Gene therapy targeting nuclear factor-kappaB: towards clinical application in inflammatory diseases and cancer. Curr Gene Ther 2009, 9:160-170. 10.2174/156652309788488569, 2864453, 19519361.
13. Duan W, Jin X, Li Q, Tashiro S, Onodera S, Ikejima T. Silibinin induced autophagic and apoptotic cell death in HT1080 cells through a reactive oxygen species pathway. J Pharmacol Sci 2010, 113:48-56. 10.1254/jphs.09315FP, 20431246.
14. Luo J, Kamata H, Karin M. The anti-death machinery in IKK/NF-kappaB signaling. J Clin Immunol 2005, 25:541-550. 10.1007/s10875-005-8217-6, 16380818.
15. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005, 5:297-309. 10.1038/nrc1588, 15803156.
16. Lin Y, Bai L, Chen W, Xu S. The NF-kappaB activation pathways, emerging molecular targets for cancer prevention and therapy. Expert Opin Ther Targets 2010, 14:45-55. 10.1517/14728220903431069, 3043547, 20001209.
17. Fillmann H, Kretzmann N, San-Miguel B, Llesuy S, Marroni N, González-Gallego J, Tuñón M. Glutamine inhibits over-expression of pro-inflammatory genes and down-regulates the nuclear factor kappaB pathway in an experimental model of colitis in the rat. Toxicology 2007, 236:217-226. 10.1016/j.tox.2007.04.012, 17543437.
18. Millea P. N-acetylcysteine: multiple clinical applications. Am Fam Physician 2009, 80:265-269.
19. Moreno-Otero R, Trapero-Marugán M. Hepatoprotective effects of antioxidants in chronic hepatitis C. World J Gastroenterol 2010, 16:1937-1938. 10.3748/wjg.v16.i15.1937, 2856839, 20397276.
20. Wanamarta A, van Rijn J, Blank L, Haveman J, van Zandwijk N, Joenje H. Effect of N-acetylcysteine on the antiproliferative action of X-rays or bleomycin in cultured human lung tumor cells. J Cancer Res Clin Oncol 1989, 115:340-344. 10.1007/BF00400960, 2474548.
21. Morley N, Curnow A, Salter L, Campbell S, Gould D. N-acetyl-L-cysteine prevents DNA damage induced by UVA, UVB and visible radiation in human fibroblasts. J Photochem Photobiol B 2003, 72:55-60. 10.1016/j.jphotobiol.2003.06.004, 14644566.
22. De Flora S, D'Agostini F, Masiello L, Giunciuglio D, Albini A. Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int J Cancer 1996, 67:842-848. 10.1002/(SICI)1097-0215(19960917)67:6<842::AID-IJC14>3.0.CO;2-3, 8824557.
23. Denizot F, Lang R. Rapid colorimetric assay for cell growth and survival. Modifications to the tetrazolium dye procedure giving improved sensitivity and reliability. J Immunol Methods 1986, 89:271-277.
24. Gutierrez MB, Miguel BS, Villares C, Gallego JG, Tunon MJ. Oxidative stress induced by Cremophor EL is not accompanied by changes in NF-kappaB activation or iNOS expression. Toxicology 2006, 222:125-131. 10.1016/j.tox.2006.02.002, 16533553.
25. Brasil LJ, San-Miguel B, Kretzmann NA, Amaral JL, Zettler CG, Marroni N, Gonzalez-Gallego J, Tunon MJ. Halothane induces oxidative stress and NF-kappaB activation in rat liver: protective effect of propofol. Toxicology 2006, 227:53-61. 10.1016/j.tox.2006.07.013, 16965849.
26. Tichopad A, Bar T, Pecen L, Kitchen R, Kubista M, Pfaffl M. Quality control for quantitative PCR based on amplification compatibility test. Methods 2010, 50:308-312. 10.1016/j.ymeth.2010.01.028, 20109549.
27. Pfaffl M. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001, 29:e45. 10.1093/nar/29.9.e45, 55695, 11328886.
28. Yano H. Inhibitory function of interferon on hepatocarcinogenesis. Oncology 2008, 75(Suppl 1):22-29.
29. Yano H, Basaki Y, Oie S, Ogasawara S, Momosaki S, Akiba J, Nishida N, Kojiro S, Ishizaki H, Moriya F, et al. Effects of IFN-alpha on alpha-fetoprotein expressions in hepatocellular carcinoma cells. J Interferon Cytokine Res 2007, 27:231-238. 10.1089/jir.2006.0135, 17348822.
30. Caglar M, Sari O, Akcan Y. Prediction of therapy response to interferon-alpha in chronic viral hepatitis-B by liver and hepatobiliary scintigraphy. Ann Nucl Med 2002, 16:511-514. 10.1007/BF02988654, 12508847.
31. Guan D, Xu Y, Yang M, Wang H, Wang X, Shen Z. N-acetyl cysteine and penicillamine induce apoptosis via the ER stress response-signaling pathway. Mol Carcinog 2010, 49:68-74.
32. Herzer K, Hofmann T, Teufel A, Schimanski C, Moehler M, Kanzler S, Schulze-Bergkamen H, Galle P. IFN-alpha-induced apoptosis in hepatocellular carcinoma involves promyelocytic leukemia protein and TRAIL independently of p53. Cancer Res 2009, 69:855-862. 10.1158/0008-5472.CAN-08-2831, 19141642.
33. Lim D, Jeong Y, Tyner A, Park J. Induction of cell cycle arrest and apoptosis in HT-29 human colon cancer cells by the dietary compound luteolin. Am J Physiol Gastrointest Liver Physiol 2007, 292:G66-G75.
34. Bekisz J, Baron S, Balinsky C, Morrow A, Zoon K. Antiproliferative Properties of Type I and Type II Interferon. Pharmaceuticals (Basel) 2010, 3:994-1015.
35. Hagiwara S, Kudo M, Ueshima K, Chung H, Yamaguchi M, Takita M, Haji S, Kimura M, Arao T, Nishio K, Park A, Munakata H. The cancer stem cell marker CD133 is a predictor of the effectiveness of S1+ pegylated interferon alpha-2b therapy against advanced hepatocellular carcinoma. J Gastroenterol 2010, 46:212-221.
36. Su W, Liu W, Cheng C, Chou Y, Hung K, Huang W, Wu C, Li Y, Shiau A, Lai M. Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities. FEBS Lett 2009, 583:2793-2798. 10.1016/j.febslet.2009.07.027, 19619545.
37. García A, Morales P, Rafter J, Haza A. N-Nitrosopiperidine and N-Nitrosodibutylamine induce apoptosis in HepG2 cells via the caspase dependent pathway. Cell Biol Int 2009, 33:1280-1286. 10.1016/j.cellbi.2009.08.015, 19748591.
38. Chen L, Zhang Q, Chang W, Du Y, Zhang H, Cao G. Viral and host inflammation-related factors that can predict the prognosis of hepatocellular carcinoma. Eur J Cancer 2012, .
39. Ceballos MP, Parody JP, Alvarez ML, Ingaramo PI, Carnovale CE, Carrillo MC. Interferon-α2b and transforming growth factor-β1 treatments on HCC cell lines: Are Wnt/β-catenin pathway and Smads signaling connected in hepatocellular carcinoma?. Biochem Pharmacol 2011, 82:1682-1691. 10.1016/j.bcp.2011.08.001, 21843516.
40. Thompson MD, Dar MJ, Monga SP. Pegylated interferon alpha targets Wnt signaling by inducing nuclear export of β-catenin. J Hepatol 2011, 54:506-512. 10.1016/j.jhep.2010.07.020, 3052972, 21093092.
41. North TE, Babu IR, Vedder LM, Lord AM, Wishnok JS, Tannenbaum SR, Zon LI, Goessling W. PGE2-regulated wnt signaling and N-acetylcysteine are synergistically hepatoprotective in zebrafish acetaminophen injury. Proc Natl Acad Sci U S A 2010, 107:17315-17320. 10.1073/pnas.1008209107, 2951415, 20855591.
42. Zhou M, Gu L, Zhu N, Woods W, Findley H. Transfection of a dominant-negative mutant NF-kB inhibitor (IkBm) represses p53-dependent apoptosis in acute lymphoblastic leukemia cells: interaction of IkBm and p53. Oncogene 2003, 22:8137-8144. 10.1038/sj.onc.1206911, 14603254.
43. Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 2009, 8:33-40. 10.1038/nrd2781, 2729321, 19116625.
44. Jost P, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007, 109:2700-2707.
45. Li J, Tu H, Dai G, Dai Y, Wu Q, Shi Q, Cao Q, Li Z. N-acetyl cysteine inhibits human signet ring cell gastric cancer cell line (SJ-89) cell growth by inducing apoptosis and DNA synthesis arrest. Eur J Gastroenterol Hepatol 2007, 19:769-774. 10.1097/MEG.0b013e3282202bda, 17700262.
46. Kim K, Rhim T, Choi I, Kim S. N-acetylcysteine induces cell cycle arrest in hepatic stellate cells through its reducing activity. J Biol Chem 2001, 276:40591-40598. 10.1074/jbc.M100975200, 11509553.
47. Chen GQY, Yao J, Jiang Q, Lin X, Chen F, Lin F, Lin M, Lin L, Zhu P. Construction of NF-kappaB-targeting RNAi adenovirus vector and the effect of NF-kappaB pathway on proliferation and apoptosis of vascular endothelial cells. Mol Bio Rep 2010, 38:3089-3094.
48. Schubert S, Neeman I, Resnick N. A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J 2002, 16:1931-1933.
49. Vercelino R, Crespo I, de Souza G, Cuevas M, de Oliveira M, Marroni N, González-Gallego J, Tuñón M. S-nitroso-N-acetylcysteine attenuates liver fibrosis in cirrhotic rats. J Mol Med 2010, 88:401-411. 10.1007/s00109-009-0577-6, 20062961.
50. Havre P, O'Reilly S, McCormick J, Brash D. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicillamine. Cancer Res 2002, 62:1443-1449.
51. Ohata K, Ichikawa T, Nakao K, Shigeno M, Nishimura D, Ishikawa H, Hamasaki K, Eguchi K. Interferon alpha inhibits the nuclear factor kappa B activation triggered by X gene product of hepatitis B virus in human hepatoma cells. FEBS Lett 2003, 553:304-308. 10.1016/S0014-5793(03)01034-2, 14572641.
52. Alexopoulou L, Holt A, Medzhitov R, Flavell R. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 2001, 413:732-738. 10.1038/35099560, 11607032.
53. Manna S, Mukhopadhyay A, Aggarwal B. IFN-alpha suppresses activation of nuclear transcription factors NF-kappa B and activator protein 1 and potentiates TNF-induced apoptosis. J Immunol 2000, 165:4927-4934.
54. Bassères D, Baldwin A. Nuclear factor-kappaB and inhibitor of kappaB kinase pathways in oncogenic initiation and progression. Oncogene 2006, 25:6817-6830. 10.1038/sj.onc.1209942, 17072330.